Form 4: Regeneron Director Thompson Acquires Shares, Options

Regeneron Pharmaceuticals Director Craig B. Thompson reported the acquisition of 155 restricted stock units and 1,962 non-qualified stock options.

Summary

• Craig B. Thompson, a Director of Regeneron Pharmaceuticals, Inc. (REGN), acquired additional equity on January 2, 2026.
• Thompson acquired 155 shares of common stock in the form of time-based vesting restricted stock units.
• Thompson also acquired 1,962 non-qualified stock options with an exercise price of $772.76 per share.
• These options have an expiration date of January 2, 2036, and will become exercisable partially on the date of the first annual meeting following the grant date, with the remainder exercisable on the first anniversary of the grant date.
• Following these transactions, Thompson beneficially owns 775 shares of common stock and 1,962 derivative securities (options).

Sentiment

Score: 7

Explanation: The acquisition of equity by a director, even through grants, is generally viewed positively as it aligns management's interests with shareholders. It indicates continued commitment and belief in the company's future prospects.

Positives

• A director acquiring additional equity, even through grants, aligns their interests with shareholders.
• The acquisition of 155 restricted stock units (RSUs) provides direct ownership of company stock upon vesting.
• The grant of 1,962 non-qualified stock options provides a long-term incentive for the director to contribute to the company's stock price appreciation.

Future Outlook

The vesting schedule for the restricted stock units and the exercisability of the stock options indicate a long-term incentive structure for the director, aligning future performance with equity value.

Industry Context

This filing reflects a common practice in the pharmaceutical and biotechnology industry where directors and executives receive equity-based compensation, such as restricted stock units and stock options, to incentivize long-term performance and align their interests with shareholders. Regeneron, a major player in the biopharmaceutical sector, uses these mechanisms as part of its overall compensation strategy to attract and retain top talent.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a director is a standard compensation practice across the biopharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Pfizer frequently utilize similar equity-based incentives for their non-employee directors and executives.
• The specific number of units and options granted would typically be benchmarked against peer companies of similar market capitalization and industry standing to ensure competitive compensation packages. Without specific peer compensation data, a direct quantitative comparison is not feasible from this filing alone, but the type of compensation is consistent with industry norms.

Related Party Transactions

• The reported transactions are related party transactions, as they involve the acquisition of company equity by a director, Craig B. Thompson.

Stakeholder Impact

• Shareholders: The director's increased equity stake aligns their interests with shareholders, potentially fostering long-term value creation.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The restricted stock units will vest over time.
• The non-qualified stock options will become exercisable partially on the date of the Issuer's first annual meeting following the grant date, and the remainder on the first anniversary of the grant date.

Key Dates

Recommendation

The filing reports standard equity compensation grants to a director, which is a positive signal of alignment between management and shareholder interests. However, as these are grants rather than open market purchases, they do not necessarily indicate a strong conviction for immediate stock price appreciation, thus a 'hold' recommendation is appropriate, acknowledging the positive alignment without suggesting a strong buy or sell action based solely on this filing.

Keywords

Regeneron Pharmaceuticals, REGN, Craig B. Thompson, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant